Stephanie C Chen1, Scott Yh Kim2,3. 1. Department of Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD, USA. 2. Department of Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD, USA scott.kim@nih.gov. 3. Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.
Abstract
BACKGROUND/AIMS: Standard of care pragmatic clinical trials that compare treatments already in use could improve care and reduce costs, but there is considerable debate about the research risks of standard of care pragmatic clinical trials and how to apply informed consent regulations to such trials. We sought to develop a framework integrating the insights from opposing sides of the debate. METHODS: We developed a formal risk-benefit analysis framework for standard of care pragmatic clinical trials and then applied it to key provisions of the US federal regulations. RESULTS: Our formal framework for standard of care pragmatic clinical trial risk-benefit analysis takes into account three key considerations: the ex ante estimates of risks and benefits of the treatments to be compared in a standard of care pragmatic clinical trial, the allocation ratios of treatments inside and outside such a trial, and the significance of some participants receiving a different treatment inside a trial than outside the trial. The framework provides practical guidance on how the research ethics regulations on informed consent should be applied to standard of care pragmatic clinical trials. CONCLUSION: Our proposed formal model makes explicit the relationship between the concepts used by opposing sides of the debate about the research risks of standard of care pragmatic clinical trials and can be used to clarify the implications for informed consent.
BACKGROUND/AIMS: Standard of care pragmatic clinical trials that compare treatments already in use could improve care and reduce costs, but there is considerable debate about the research risks of standard of care pragmatic clinical trials and how to apply informed consent regulations to such trials. We sought to develop a framework integrating the insights from opposing sides of the debate. METHODS: We developed a formal risk-benefit analysis framework for standard of care pragmatic clinical trials and then applied it to key provisions of the US federal regulations. RESULTS: Our formal framework for standard of care pragmatic clinical trial risk-benefit analysis takes into account three key considerations: the ex ante estimates of risks and benefits of the treatments to be compared in a standard of care pragmatic clinical trial, the allocation ratios of treatments inside and outside such a trial, and the significance of some participants receiving a different treatment inside a trial than outside the trial. The framework provides practical guidance on how the research ethics regulations on informed consent should be applied to standard of care pragmatic clinical trials. CONCLUSION: Our proposed formal model makes explicit the relationship between the concepts used by opposing sides of the debate about the research risks of standard of care pragmatic clinical trials and can be used to clarify the implications for informed consent.
Keywords:
Comparative effectiveness randomized control trials; informed consent; pragmatic randomized control trials; research ethics; research risk analysis
Authors: Steven M Brunelli; Glenn M Chertow; Elizabeth D Ankers; Edmund G Lowrie; Ravi Thadhani Journal: Kidney Int Date: 2010-01-20 Impact factor: 10.612
Authors: Kim S Thomas; Angela M Crook; Andrew J Nunn; Katharine A Foster; James M Mason; Joanne R Chalmers; Ibrahim S Nasr; Richard J Brindle; John English; Sarah K Meredith; Nicholas J Reynolds; David de Berker; Peter S Mortimer; Hywel C Williams Journal: N Engl J Med Date: 2013-05-02 Impact factor: 91.245
Authors: Stuart G Nicholls; Kelly Carroll; Merrick Zwarenstein; Jamie C Brehaut; Charles Weijer; Spencer P Hey; Cory E Goldstein; Ian D Graham; Jeremy M Grimshaw; Joanne E McKenzie; Dean A Fergusson; Monica Taljaard Journal: Trials Date: 2019-12-23 Impact factor: 2.279
Authors: Nyiramugisha K Niyibizi; Candace D Speight; Gabriel Najarro; Andrea R Mitchell; Ofer Sadan; Yi-An Ko; Neal W Dickert Journal: BMC Med Ethics Date: 2022-03-27 Impact factor: 2.652
Authors: Cory E Goldstein; Charles Weijer; Jamie C Brehaut; Dean A Fergusson; Jeremy M Grimshaw; Austin R Horn; Monica Taljaard Journal: BMC Med Ethics Date: 2018-02-27 Impact factor: 2.652
Authors: Katherine R Courtright; Scott D Halpern; Steven Joffe; Susan S Ellenberg; Jason Karlawish; Vanessa Madden; Nicole B Gabler; Stephanie Szymanski; Kuldeep N Yadav; Laura M Dember Journal: Trials Date: 2017-10-11 Impact factor: 2.279